Cell Reports

Structural Basis of Sarco/Endoplasmic Reticulum Ca\(^{2+}\)-ATPase 2b Regulation via Transmembrane Helix Interplay

Graphical Abstract

Highlights

- Crystal structure was solved for human SERCA2b and SERCA2a in E1-2Ca\(^{2+}\)-AMPPCP state
- The location and orientation of TM11 helix characteristic of SERCA2b were revealed
- Amino acid residues involved in interaction with TM11 were identified
- Molecular mechanisms of TM11-mediated SERCA2b regulation are proposed

Authors
Michio Inoue, Nanami Sakuta, Satoshi Watanabe, ..., Tomoya Tsukazaki, Kazuhiro Nagata, Kenji Inaba

Correspondence
kinaba@tagen.tohoku.ac.jp

In Brief
Inoue et al. present a crystal structure of human SERCA2b, a ubiquitously expressed Ca\(^{2+}\)-ATPase that facilitates Ca\(^{2+}\) uptake into the endoplasmic reticulum and thereby plays central roles in intracellular calcium homeostasis. The structural and biochemical analyses clarify molecular mechanisms of SERCA2b regulation via TM helix interplay.
Structural Basis of Sarco/Endoplasmic Reticulum Ca\(^{2+}\)-ATPase 2b Regulation via Transmembrane Helix Interplay

Michio Inoue,1,6 Nanami Sakuta,1,6 Satoshi Watanabe,1,6 Yuxia Zhang,1,6 Kunihiro Yoshikai,2 Yoshiki Tanaka,2 Ryo Ushioda,2,6 Yukinari Kato,3 Junichi Takagi,6 Tomoya Tsukazaki,1 Kazuhiro Nagata,3,6 and Kenji Inaba1,6,7,*

1Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Sendai 980-8577, Japan
2Graduate School of Biological Sciences, NARA Institute of Science and Technology, Ikoma 630-0192, Japan
3Faculty of Life Sciences, Kyoto Sangyo University, Kyoto 603-0875, Japan
4Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan
5Institute for Protein Research, Osaka University, Suita 565-0871, Japan
6Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Saitama, Kawaguchi, Japan
7Lead Contact

*Correspondence: kinaba@tagen.tohoku.ac.jp
https://doi.org/10.1016/j.celrep.2019.03.106

SUMMARY

SARCO/endoplasmic reticulum (ER) Ca\(^{2+}\)-ATPase 2b (SERCA2b) is a ubiquitously expressed membrane protein that facilitates Ca\(^{2+}\) uptake from the cytosol to the ER. SERCA2b includes a characteristic 11\(^{th}\) transmembrane helix (TM11) followed by a luminal tail, but the structural basis of SERCA regulation by these C-terminal segments remains unclear. Here, we determined the crystal structures of SERCA2b and its C-terminal splicing variant SERCA2a, both in the E1-2Ca\(^{2+}\)-adenylyl methylenediphosphonate (AMPPCP) state. Despite discrepancies with the previously reported structural model of SERCA2b, TM11 was found to be located adjacent to TM10 and to interact weakly with a part of the L8/9 loop and the N-terminal end of TM10, thereby inhibiting the SERCA2b catalytic cycle. Accordingly, mutational disruption of the interactions between TM11 and its neighboring residues caused SERCA2b to display SERCA2a-like ATPase activity. We propose that TM11 serves as a key modulator of SERCA2b activity by fine-tuning the intramolecular interactions with other transmembrane regions.

INTRODUCTION

The endoplasmic reticulum (ER) is an essential organelle responsible for Ca\(^{2+}\) storage, in which sarco/endoplasmic reticulum Ca\(^{2+}\)-ATPase (SERCA) imports Ca\(^{2+}\) against a huge (>1,000-fold) Ca\(^{2+}\) concentration gradient between the ER and the cytosol. Human cells contain 3 different SERCA isoforms divided into 11 splice variants (SERCA1a–1b, -2a–2c, and -3a–3f) (Altschuler et al., 2012). SERCA1a and SERCA2a are expressed mainly in skeletal and cardiac muscle, respectively, while SERCA2b is a ubiquitously expressed housekeeping membrane protein responsible for maintaining Ca\(^{2+}\) homeostasis in cells. Residues 1–993 of SERCA2b share an identical amino acid sequence with its splice variant SERCA2a, but the former also possesses a 49-residue C-terminal extension (Campbell et al., 1991) (Figure 1A) that is predicted to contain the 11\(^{th}\) transmembrane helix (TM11) and the 12-residue luminal extension (LE) (Campbell et al., 1992), SERCA2a and SERCA1a isoforms, both of which lack TM11 and the C-terminal tail, exhibit higher ATPase activity and lower affinity for Ca\(^{2+}\) than SERCA2b (Dode et al., 2003; Verboomen et al., 1992, 1994), indicating a regulatory role for the C-terminal extension in SERCA2b. Accordingly, truncation of the C-terminal 49 residues resulted in a ~2-fold higher turnover rate than wild-type (WT) SERCA2b (Vandecaetsbeek et al., 2009; Verboomen et al., 1994).

A docking model of SERCA2b predicted that TM11 interacts with TM7 and TM10 and that the LE segment binds the groove formed between loops L5/6 and L7/8 (Vandecaetsbeek et al., 2009). Exogenous addition of a synthetic LE peptide (Met1039–Ser1042) to SERCA2a inhibits the ATPase activity and increases the apparent Ca\(^{2+}\) affinity, possibly by stabilizing the Ca\(^{2+}\)-bound E1-2Ca\(^{2+}\) state, suggesting that the LE segment serves as a functional modulator of SERCA2b (Vandecaetsbeek et al., 2009). Moreover, co-reconstitution of a synthetic TM11 peptide (Gly1013–Tyr1030) with SERCA1a has a similar functional effect (lower V\(_{\text{max}}\) and higher Ca\(^{2+}\) affinity) to that of LE (Gorski et al., 2012). However, the molecular mechanisms underpinning TM11-mediated SERCA2b regulation remain poorly understood due to a lack of structural information on SERCA2b.

Herein, we present crystal structures of human SERCA2b and SERCA2a, both in the E1-2Ca\(^{2+}\)-adenylyl methylenediphosphonate (AMPPCP) state (Figure 1B). While crystal structures were recently released for E2-AlF\(_{4}^{-}\) - and E1-2Ca\(^{2+}\)-AMPPCP forms of SERCA2a from pig ventricular muscle (Sitsel et al., 2019), we report on the crystal structure of SERCA2b. The crystal structure, in combination with anomalous signal analysis using the single-wavelength anomalous dispersion (SAD) dataset of selenium methionine (SeMet)-labeled SERCA2b, revealed that despite discrepancies with the previously predicted model, TM11 is...
located adjacent to TM10 and does not interact with TM7; instead, the N-terminal and C-terminal ends of TM11 interact with a part of the L8/9 loop and TM10, respectively. Structure-based biochemical studies demonstrated that the functional properties of SERCA2b were significantly affected by the mutations of TM11 residues interacting with the L8/9 loop or TM10. We propose that TM11 serves to fine-tune the turnover rate and Ca$^{2+}$ affinity of SERCA2b through the interplay with other TM regions.

**RESULTS AND DISCUSSION**

**Overall Structures of SERCA2b and SERCA2a**

We developed human stable cell lines expressing recombinant human SERCA2b and SERCA2a with an N-terminal dodecapeptide PA-tag (GVAMPAGEDDVV) using the PiggyBac Cuxmate Switch Inducible system. For stable expression of SERCA2b or SERCA2a, HEK293T cells harboring either one of the SERCA2 genes and the promoter sequence transposed

---

### Figure 1. Alignment of the Amino Acid Sequences of Human SERCA Family Members and Catalytic Cycle Exerted by SERCA Family Enzymes

**A** Transmembrane helices TM1–TM10 and TM11 are shown in green and red, respectively. Cytosolic A, N, and P domains are shown in cyan, salmon pink, and orange, respectively. Residues Phe1018 and Val1029 are blue.

**B** Key states generated along the ATP-driven Ca$^{2+}$ pump cycle of SERCA. Note that AMPPCP, a non-hydrolyzable ATP analog, traps the Ca$^{2+}$-bound state of SERCA to generate the E1-2Ca$^{2+}$-AMPPCP state.
onto the chromosomes were established through selection by repeated passage in the presence of 10 µg/mL puromycin. Recombinant SERCA2b and SERCA2a were overexpressed using cumate induction (Ushioda et al., 2016) and purified by the established methodology for rapid high-yield purification using the high-affinity antibody NZ-1 (Fujii et al., 2016), followed by size-exclusion chromatography (Figures S1A and S1B). SERCA2a and SERCA2b fully purified in the presence of 1 mM DTT were obtained with a yield of 0.6–1 mg/L culture medium. SERCA2b and SERCA2a were crystallized in complex with Ca²⁺ and AMPPCP, a non-hydrolyzable ATP analog, using the lipidic cubic phase (LCP) method (Figure S1C). X-ray diffraction images of SERCA2b (Figure S1D) were collected from >10 microcrystals, and images of SERCA2a were collected from a single crystal, at SPring-8 beamline BL32XU, and refined to 3.45 and 3.2 Å resolution, respectively (Table 1). Phases were determined by molecular replacement using a previously published crystal structure of AMPPCP-bound SERCA1a (PDB: 1T5S) as a search model.

In both SERCA2b and SERCA2a, clear electron density was observed for the cytosolic A, N, and P domains, and the 10 TM helices (Figure 2A; Videos S1 and S2), allowing model building of their overall structures (Figure 2B). The locations of the 3 cytosolic domains and the arrangement of TM1–TM10 are almost identical to those previously reported for AMPPCP-bound SERCA1a (Sørensen et al., 2004; Toyoshima and Mizutani, 2004). The modes of ATP binding and calcium coordination in SERCA2b and SERCA2a are also similar to those in SERCA1a, suggesting common mechanisms of ATP hydrolysis and Ca²⁺ transport among the SERCA family members (Figures 1B, S2, and S3). In agreement with the use of reduced forms of SERCA2b and SERCA2a in crystallization, the electron density map of the L7/8 loop indicated that both Cys875 and Cys887 were in reduced form (Figure S4). Enzymatic assays showed that the ATPase activity of SERCA2b reconstituted into liposome was 2-fold lower than that of SERCA2a (Vandecaetsbeek et al., 2009). Thus, our SERCA2 preparations retained their intrinsic activities.

Modeling and Physical Location of TM11

Significant electron density was visible adjacent to TM10 in SERCA2b, but not in SERCA2a (Figures 2A and 2B; Videos S1 and S2), indicating that it is derived from TM11 and is characteristic of SERCA2b. To further corroborate our assignment

### Table 1. X-Ray Diffraction Data Collection and Refinement Statistics

<table>
<thead>
<tr>
<th></th>
<th>SERCA2b</th>
<th>SERCA2a</th>
<th>SeMet-Labeled SERCA2b</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Data Collection</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beamline</td>
<td>SPring-8 BL32XU</td>
<td>SPring-8 BL32XU</td>
<td>SPring-8 BL32XU</td>
</tr>
<tr>
<td>Wavelength</td>
<td>1.000</td>
<td>1.000</td>
<td>0.9780</td>
</tr>
<tr>
<td>Space group</td>
<td>P2₁,2₂</td>
<td>P2₁,2₂</td>
<td>P2₁,2₂</td>
</tr>
<tr>
<td><strong>Cell Dimensions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a, b, c (Å)</td>
<td>165.08, 84.64, 118.83</td>
<td>165.58, 84.36, 122.19</td>
<td>165.31, 84.87, 121.22</td>
</tr>
<tr>
<td>Oscillation × No. crystals</td>
<td>5° × 21, 10° × 25</td>
<td>180° × 1</td>
<td>10° × 42</td>
</tr>
<tr>
<td>Resolution (Å)²</td>
<td>48.2–3.45 (3.57–3.45)</td>
<td>49.48–3.20 (3.31–3.20)</td>
<td>49.48–5.5 (5.70–5.50)</td>
</tr>
<tr>
<td>Completeness (%)²</td>
<td>93.7 (77.0)</td>
<td>100 (99.9)</td>
<td>99.1 (99.7)</td>
</tr>
<tr>
<td>Redundancy³</td>
<td>8.9 (5.1)</td>
<td>6.6 (6.6)</td>
<td>14.0 (14.6)</td>
</tr>
<tr>
<td>I/σ (I)³</td>
<td>4.7 (1.8)</td>
<td>4.7 (1.3)</td>
<td>4.2 (1.3)</td>
</tr>
<tr>
<td>R&lt;sub&gt;meas&lt;/sub&gt; (%)²,³</td>
<td>33.8 (91.7)</td>
<td>26.4 (147)</td>
<td>44.6 (304)</td>
</tr>
<tr>
<td>CC&lt;sub&gt;1/2&lt;/sub&gt;³</td>
<td>0.963 (0.511)</td>
<td>0.999 (0.524)</td>
<td>0.660 (0.404)</td>
</tr>
<tr>
<td><strong>Refinement Statistics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resolution (Å)³</td>
<td>48.2–3.45</td>
<td>49.48–3.20</td>
<td>–</td>
</tr>
<tr>
<td>R&lt;sub&gt;work&lt;/sub&gt;/R&lt;sub&gt;free&lt;/sub&gt; (%)³</td>
<td>24.9/30.8</td>
<td>21.1/25.6</td>
<td>–</td>
</tr>
<tr>
<td>RMSDs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bond lengths (Å)</td>
<td>0.007</td>
<td>0.010</td>
<td>–</td>
</tr>
<tr>
<td>Bond angles (°)</td>
<td>0.726</td>
<td>0.736</td>
<td>–</td>
</tr>
<tr>
<td>Ramachandran Plot</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Favored (%)</td>
<td>94.0</td>
<td>94.0</td>
<td>–</td>
</tr>
<tr>
<td>Allowed (%)</td>
<td>6.0</td>
<td>6.0</td>
<td>–</td>
</tr>
<tr>
<td>Outliers (%)</td>
<td>0.0</td>
<td>0.0</td>
<td>–</td>
</tr>
</tbody>
</table>

²Values in parentheses are for the highest-resolution shell.
³R<sub>meas</sub> = Σ|Iᵢ(hkl) – <I(hkl)>|/ΣIᵢ(hkl), where Iᵢ(hkl) is the i-th observed intensity and <I(hkl)> is the average intensity from multiple observations.
⁴R<sub>work</sub> = Σ|Fᵦ – Fᵢ|/ΣFᵦ, where Fᵦ and Fᵢ are observed and calculated structure factors, respectively.
⁵R<sub>free</sub> is R factor for a selected subset (5%) of randomly chosen reflections that were omitted in prior refinement calculations.
of TM11, we crystallized SeMet-substituted recombinant SERCA2b and collected a diffraction dataset at the Se K-edge wavelength (0.9780 Å). An anomalous difference Fourier map contoured at 3σ identified 20 of the 32 selenium sites (Figure 3A). Of particular note, a significant anomalous peak (4.0σ) was observed close to the putative TM11 backbone, likely derived from Met1023 located in TM11 (Figure 3B). Based on this anomalous peak and the 2Fo–Fc map at 3.45 Å, we modeled the F1018–Y1030 segment of the TM11 helix (Figures 3B and 3C), as previously performed on disulfide bond formation protein B (DsbB), a membranous sulfhydryl oxidase from Escherichia coli (Inaba et al., 2006, 2009). Consequently, the N- and C-terminal ends of TM11 were found to interact with a part of the L8/9 loop and the ER luminal end of TM10, respectively; Trp927 (L8/9) forms van der Waals contacts with Phe1018 (TM11), while Val1029 (TM11) is surrounded by Leu967, Leu970, and Lys971 (TM10; Figure 3C).

The TM11 region has high B-factor values (135–186 Å²), suggesting its fluctuating property and/or partially disordered helical conformation (Figure 3D). In support of this, the electron density map of SERCA2b at 1.5–2.0σ counter levels (Figure S5) showed that similar to the L7/8 and L9/10 loops, the TM11 region had fragmented electron density with lower intensity compared to the other TM helices. Accordingly, TM11 is significantly isolated from the TM helix bundle domain, generating a cavity with a volume of >35 Å³ between TM10 and TM11 and a distance of 13.7 Å between the Ca atoms of Ile977 and Met1023 (Figure 3E). No electron density higher than the 0.4σ contour level was observed in this cavity, suggesting that there are few, if any, tightly bound phospholipids that intervene between these 2 TM helices. Electron density is missing also for the L10/11 loop and the ER luminal tail following TM11 (Figure 1A). It is likely that these 2 regions are even more fluctuating and/or disordered than TM11. Thus, TM11 and the subsequent tail appear to engage in only limited interactions with other TM regions of SERCA2b. The present finding tempts us to speculate that TM11 may be readily released from the TM helix bundle domain in other intermediate states. It will be interesting to explore
whether TM11 serves to fine-tune the SERCA2b activity through the association with or release from the TM helix bundle domain to maintain the Ca\(^{2+}\) homeostasis in the ER (see also the following sections).

**Roles of TM11 in SERCA2b Regulation**

To quantify the specific activities of SERCA2b and SERCA2a in the membrane-embedded state, we first prepared microsomes of HEK293T cells overexpressing WT SERCA2b and SERCA2a. In agreement with previous results obtained using microsomes of COS cells overexpressing SERCA2a or SERCA2b (Vande-caetsbeek et al., 2009), the \(V_\text{max}\) value of SERCA2b (1.8 \(\times\) 10\(^2\) min\(^{-1}\)) was nearly 2.3-fold lower than that of SERCA2a (4.2 \(\times\) 10\(^2\) min\(^{-1}\)), while the \(K_d\) values for Ca\(^{2+}\) binding to SERCA2b and SERCA2a were 0.21 and 0.35 \(\mu\)M, respectively (Figure 4; Table S1). Thus, SERCA2b displayed compromised ATPase activity and increased apparent affinity for Ca\(^{2+}\) compared with SERCA2a, implying that TM11 and the subsequent luminal

tail, which are characteristic of SERCA2b, serve as an intramolecular uncompetitive inhibitor.

To explore the functional roles of the intramolecular interactions between TM11 and its neighboring residues, and thereby verify the actual occurrence of the interactions, Phe1018 and Val1029 on TM11 were simultaneously mutated to glycine, and the ATPase activity of the resultant mutant (F1018G/V1029G) was measured at various Ca\(^{2+}\) concentrations. Microsomal SERCA2b F1018G/V1029G displayed a \(~1.7\)-fold higher \(V_\text{max}\) value and \(~1.5\)-fold lower affinity for Ca\(^{2+}\) than microsomal SERCA2b WT (Figure 4). Thus, disruption of the interactions between TM11 and its neighboring TM regions caused the catalytic turnover rate and Ca\(^{2+}\)-binding affinity of SERCA2b to resemble those of SERCA2a. Meanwhile, neither of the single mutations F1018G or V1029G greatly affected the ATPase activity of the resultant

In this context, Mikkelsen et al. (2018) demonstrated that either the mutation of Glu917, a residue located in the L8/9 loop, or of Arg835, a TM7 residue hydrogen bonded to Glu917, abrogated the inhibitory effect of TM11. It was inferred that the specific interactions between the L8/9 loop and TM7 may be
involved in regulating the position of TM11 and its interactions with the surrounding regions. However, the present crystallographic study reveals that TM11 is located on the opposite side to TM7, close to TM10, and makes no direct contact with TM7 (Figure 1B). We surmise that mutational disruption of the Arg835 (TM7)-Glu917 (L8/9) interaction could greatly alter the TM7 (Figure 1B). We surmise that mutational disruption of the Arg835 (TM7)-Glu917 (L8/9) interaction could greatly alter the L8/9 conformation, thereby diminishing interactions between L8/9 and TM11 and hence reducing inhibition by TM11.

**Different Binding Sites for TM11 and Phospholamban and Sarcolipin Proteins in SERCA Family Members**

It is well known that SERCA2a and SERCA1a are regulated by the small single-spanning membrane protein phospholamban (PLB) and its homologous protein sarcolipin (SLN) (Hughes et al., 1994; Odermatt et al., 1998). Similar to SERCA2a and SERCA1a, PLB and SLN are abundant in cardiac and skeletal muscle, respectively, whereas SERCA2b is expressed ubiquitously (Burk et al., 1994). The crystal structure of SERCA1a in complex with SLN demonstrated that SLN binds to the TM groove formed by TM2, TM4, TM6, and TM9 (Figure 5A) (Toyoshima et al., 2013; Winther et al., 2013). More recently, a transmembrane micropeptide, another-regulin (ALN), which is expressed ubiquitously and shares key amino acids with PLB and SLN, was identified to inhibit the Ca$^{2+}$ pump activity of SERCA2b (Anderson et al., 2016). The competition assay for binding to SERCA2b suggested that ALN interacts with the same region of the Ca$^{2+}$-ATPase as PLB and SLN. The present study revealed that TM11 is located at a completely different site from those micropeptides, suggesting that TM11 regulates SERCA activity in a different manner (for more details, see the following 2 sections). PLB and SLN are reported to bind and preferentially stabilize the Ca$^{2+}$-free E2 state and/or the E1-Mg$^{2+}$ state before Ca$^{2+}$ binding, thereby inhibiting the transition to the E1-2Ca$^{2+}$ state (MacLennan and Kranias, 2003; Toyoshima et al., 2003, 2013; Winther et al., 2013). In this context, SLN contributes to muscle-based thermogenesis in mammalian cells by uncoupling SERCA-mediated ATP hydrolysis from Ca$^{2+}$ transport (Bal et al., 2012; Ikeda et al., 2017). Previous studies showed that TM11 is critical for low rates of the E2 dephosphorylation step, E2P to E2, and the conformational transition of the dephosphoenzyme, E2 to E1 (Gorski et al., 2012), whereas the subsequent LE region prevents the E1P to E2P transition, independent of TM11 (Clausen et al., 2012; Dode et al., 2003). Thus, TM11 and the LE region likely inhibit the catalytic cycle of SERCA2b in different ways, while their possible roles in the exothermic activity of SERCA2b remains to be explored.

**Similar Binding Sites of TM11 in SERCA2b and the TM Helix of Neuroplastin in PII-type ATPase-1**

Neuroplastin (NPTN) and Basigin, members of the immunoglobulin (Ig) superfamily with a single TM helix, have recently been identified as obligatory auxiliary subunits of the plasma membrane Ca$^{2+}$ ATPase (PMCA) (Schmidt et al., 2017). PMCA proteins belong to the PII-type ATPase family, like SERCA proteins, and endogenously form a heterotetramer involving NPTN or Basigin to fulfill the Ca$^{2+}$ transport activity. The single TM helix of NPTN or Basigin plays particular roles in stabilizing and trafficking the PMCA complexes (Schmidt et al., 2017). The latest study revealed the cryo-EM structure of PMCA1 in complex with NPTN (Gong et al., 2018), in which PMCA1 assumes a conformation similar to an E1-Mg$^{2+}$ state, a transient state from E2 to E1-2Ca$^{2+}$ states. The TM helix and the Ig domain of NPTN were found to interact with TM10 and the L7/8 loop of PMCA1, respectively. The superposition of SERCA2b with the PMCA1-NPTN complex indicates that TM11 in SERCA2b is located at a similar position to the NPTN TM helix in the PMCA1-NPTN complex, even though these 2 TM helices are arranged in different angles with respect to the TM helix bundle domains (Figure 5B). The NPTN TM helix (21 residues), which is longer than SERCA2b TM11 (13 residues), interacts tightly with TM10 of PMCA1 (Figure S6A). The contact area between the NPTN TM helix and PMCA1 TM10 is 259.1 Å$^2$, while that between TM11 and TM10 in SERCA2b is 80.5 Å$^2$. Accordingly, the NPTN TM helix region has low B-factor values (50–100 Å$^2$), suggesting its rigid conformation (Figure S6B). Unlike TM11 in SERCA2b, NPTN may serve as an essential partner rather than a weakly or transiently interacting modulator of PMCA1.

**Possible Mechanisms Underlying TM11-Mediated SERCA2b Regulation**

The membranous domain of SERCA can be subdivided into 3 subdomains consisting of TM1–TM2, TM3–TM4, and TM5–TM10...
During the transition between Ca^{2+}-bound E1 and Ca^{2+}-released E2 states, the association and separation of these 3 subdomains take place to control the closing and opening of the luminal Ca^{2+} pathway (Olesen et al., 2007). Concomitantly, the TM1–TM2 subdomain undergoes striking upward and downward shifts, and TM4 becomes kinked at a conserved proline residue, influencing the orientation and intra-subdomain arrangement of TM5–TM10 (Møller et al., 2010). Although no information is yet available for the structures of SERCA2b in intermediate states other than the E1-2Ca^{2+}-AMPPCP state, it is possible that the extra TM helix weakly interacting with other TM regions serves to control such rearrangement of the TM helix bundle domain during the SERCA catalytic cycle.

In this context, when the cytosolic A, N, and P domains of SERCA2b and SERCA2a are superimposed such that the root-mean-square deviation (RMSD) of their Cz atoms is minimized, the TM1–TM2, TM3–TM4, and TM5–TM10 subdomains of SERCA2b are shifted by 2.6°–3.4° at the position of Ala327 with respect to those in SERCA2a, and end up further apart from TM11 as a consequence (Figure 6A). Accordingly, W1028 and V1029 of TM11 in SERCA2b would undergo steric clashes with L967, L970, and K971 of TM10 in SERCA2a (Figure 6A). To avoid these steric clashes, the movement of the TM helix bundle domain appears to be more restricted in SERCA2b than in SERCA2a (Figure 6B).

It has been established that SERCA family enzymes undergo significant dynamics in both the cytosolic and TM domains during the catalytic cycle (Møller et al., 2010). In this regard, we note that when any of the TM helix subdomains is superimposed between SERCA2a and SERCA2b, a slight but significant orientation shift is seen in their cytosolic domains, while there is no striking difference in the other TM helix subdomains (Figure S7). Thus, it is also interpretable that the presence of TM11 alters the tilt angle of the cytosolic domains relative to the TM helix bundle domain in the E1-2Ca^{2+}-ATP state. Although structural information for other reaction intermediates is required to completely delineate how TM11 affects the location and dynamics of each TM helix and cytosolic domain during the reaction cycle, we propose a possible role for TM11 in controlling the relative arrangement of the TM helix bundle and cytosolic domains in SERCA2b for the modulation of its activity (Figure 6B).

Further Perspectives

Functional regulation by accessory TM regions has been reported previously for other P-type ATPases. In P1B-type ATPases, 2 additional N-terminal TMs modulate the entry and exit of Zn^{2+} and Cu^{2+} ions (Gourdon et al., 2011; Wang et al., 2018).
Na⁺/K⁺-ATPase forms a heterotrimer composed of an α-subunit containing A, N, and P domains, 10 TMs, and single TM β- and γ-subunits (Morth et al., 2007). Association of the β- and γ-subunits with the α-subunit modulates the affinity for K⁺ and/or Na⁺ (Geering, 2005; Hasler et al., 2001). Moreover, in the structure of H⁺-ATPase in the AMPPCP-bound state, the C-terminal regulatory domain (R domain) lacks electron density, presumably due to high flexibility (Pedersen et al., 2007). The R domain is believed to function as an auto-inhibitor that restricts TM helix movement and/or access of ions to the membrane transport core during the reaction cycle (Morth et al., 2011). Thus, regulating the interactions between additional TM moieties and the main helix bundle domain likely represents an effective and common strategy for the functional regulation of P-type ATPases.

Several recent reports suggest that ER-resident redox enzymes such as ERdj5, ERp57, TMX1, and SEPN1 are involved in regulating SERCA2b activity (Li and Camacho, 2004; Marino et al., 2015; Raturi et al., 2016; Ushioda et al., 2016). While SEPN1 helps to maintain SERCA2b activity by protecting the hyperoxidation of the ER luminal Cys875 (Marino et al., 2015), the ER-resident disulfide reductase ERdj5 stimulates SERCA2b activity by reducing the Cys875-Cys887 disulfide in the L7/L8 loop (Ushioda et al., 2016). ER chaperones calnexin and calreticulin and the CREC (Ca²⁺-binding protein of 45 kDa [Cab45], reticulocalbin, ER Ca²⁺-binding protein of 55 kDa [ERC-55], and calumenin) family protein Cab45S also bind SERCA2b, thereby inhibiting its Ca²⁺ pump activity (Chen et al., 2016; John et al., 1998; Roderick et al., 2000). TMTC1 and TMTC2, which consist of multiple transmembrane segments and tetratricopeptide repeat (TPR)-containing adaptor domains, associate with SERCA2b to influence intracellular calcium levels (Sunryd et al., 2014). Thus, several ER luminal or membrane proteins are involved in the regulation of SERCA2b activity, although detailed mechanisms have yet to be uncovered. However, based on the findings of the present study, we surmise that such regulatory partner proteins may affect the location of TM11 and/or its interaction with other SERCA2b regions, thereby modulating SERCA2b activity but not SERCA2a activity. In line with this, the ER chaperone calnexin physically interacts with the C terminus of SERCA2b to control the Ca²⁺ store in the ER (Roderick et al., 2000). The structural insight gained in this study provides a framework for understanding the mechanism underlying TM11-mediated SERCA2b regulation for maintaining Ca²⁺ homeostasis in the ER.
STAR METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **CONTACT FOR REAGENT AND RESOURCE SHARING**
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
- **METHOD DETAILS**
  - Construction of plasmids and cell lines
  - Crystallization of SERCA2b and SERCA2a
  - Data collection and structure determination
  - Preparation and analysis of SeMet-labeled SERCA2b
  - Preparation of microsomal SERCA2b and SERCA2a
  - ATPase activity assay
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
- **DATA AND SOFTWARE AVAILABILITY**

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.celrep.2019.03.106.

ACKNOWLEDGMENTS

We thank the beamline scientists of SPring-8 and Photon Factory for their assistance with X-ray diffraction data collection. This work was supported by CREST, JST (to K.I. and K.N.), grant number JPMJCR13M6, Grants-in-Aid for Scientific Research on Innovative Areas from MEXT (15H04335 and 26116005 to K.I. and 26119007 to T.T.), the Takeda Science Foundation (to K.I.), and the Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research [BINDS] from AMED to K.I.). This work was also supported by Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research [BINDS] from AMED) to K.I.) and the Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research [BINDS] from AMED to K.I.).

AUTHOR CONTRIBUTIONS

M.I. constructed a large-scale expression system for SERCA2b and SERCA2a and established the purification methods. M.I. and J.T. prepared the vector for the overexpression of PA-tagged SERCA2b. N.S. purified SERCA2a on a large scale. M.I., N.S., K.Y., Y.T., and T.T. crystallized the vector for the overexpression of PA-tagged SERCA2b. M.I. and J.T. prepared plasmids and cell lines. K.I., R.U., and K.N. designed the study. M.I. supervised the work. M.I. and S.W. prepared the figures. K.I., M.I., and S.W. wrote the manuscript. All of the authors discussed the results and approved the manuscript.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: December 3, 2018
Revised: February 28, 2019
Accepted: March 27, 2019
Published: April 23, 2019

REFERENCES


## STAR METHODS

### KEY RESOURCES TABLE

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibodies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SERCA2 Antibody (N-19)</td>
<td>Santa Cruz Biotechnology</td>
<td>sc-8095</td>
</tr>
<tr>
<td>Donkey F(ab’)2 Anti-Goat IgG (HRP)</td>
<td>Abcam</td>
<td>Ab98519</td>
</tr>
<tr>
<td><strong>Chemicals, Peptides, and Recombinant Proteins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cumate (p-Isopropylbenzoic Acid)</td>
<td>FUJIFILM Wako Pure Chemical Corporation</td>
<td>037-06412</td>
</tr>
<tr>
<td>Phorbol 12-myristate 13-acetate</td>
<td>FUJIFILM Wako Pure Chemical Corporation</td>
<td>168-23593</td>
</tr>
<tr>
<td>Monoolein</td>
<td>Nu-Chek-Prep, Inc.</td>
<td>M-239</td>
</tr>
<tr>
<td>β, γ-Methyleneadenosine 5’-triphosphate disodium salt</td>
<td>Sigma</td>
<td>M7510</td>
</tr>
<tr>
<td>Polyethylenimine</td>
<td>Sigma</td>
<td>408727</td>
</tr>
<tr>
<td>Seleno-L-methionine</td>
<td>NACALAI TESQUE</td>
<td>02286-75</td>
</tr>
<tr>
<td>PA-SERCA2b</td>
<td>Ushioda et al., 2016</td>
<td>N/A</td>
</tr>
<tr>
<td>PA-SERCA2a</td>
<td>This study</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Critical Commercial Assays</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EnzCheck™ Phosphate Assay Kit</td>
<td>Thermo Fisher Scientific</td>
<td>E6646</td>
</tr>
<tr>
<td><strong>Deposited Data</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SERCA2b E1-AMPPCP form</td>
<td>This paper</td>
<td>PDB: 5ZTF</td>
</tr>
<tr>
<td>SERCA2a E1-AMPPCP form</td>
<td>This paper</td>
<td>PDB: 6JJU</td>
</tr>
<tr>
<td><strong>Experimental Models: Cell Lines</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human: HEK293T cells</td>
<td>ATCC</td>
<td>CRL-3216</td>
</tr>
<tr>
<td><strong>Oligonucleotides</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primer: SERCA2a forward: taatacgactcactataggg</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>Primer: SERCA2a reverse: tgcgcccccttactccagta ttcggctcgggttagtcgcggccc</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>Primer: SERCA2bF1018G forward: tacccataagga cggccacacgagagtattac</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>Primer: SERCA2bF1018G reverse: forward: catta tgacgacacccggccaggaaatcccat</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>Primer: SERCA2bV1029G forward: cggggaccact agacccataatcgtgctgtgat</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>Primer: SERCA2bV1029G reverse: tagtgctgctgtgct ataaccccagatcaccaggccc</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Recombinant DNA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasmid: pcDNA3.1/PA-SERCA2b</td>
<td>Ushioda et al., 2016</td>
<td>N/A</td>
</tr>
<tr>
<td>PiggyBac Cumate Switch Inducible Vector</td>
<td>System Biosciences, LLC, CA, USA</td>
<td>#PBQM812A-1</td>
</tr>
<tr>
<td>Super PiggyBac Transposase Expression Vector</td>
<td>System Biosciences, LLC, CA, USA</td>
<td>#PB200PA-1</td>
</tr>
<tr>
<td><strong>Software and Algorithms</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prism 7</td>
<td>GraphPad software</td>
<td>N/A</td>
</tr>
<tr>
<td>XDS</td>
<td>Kabsch, 2010</td>
<td><a href="http://xds.mpimf-heidelberg.mpg.de">http://xds.mpimf-heidelberg.mpg.de</a></td>
</tr>
<tr>
<td>KAMO</td>
<td>Yamashita et al., 2018</td>
<td>N/A</td>
</tr>
<tr>
<td>DIALS</td>
<td>Waterman et al., 2016</td>
<td>N/A</td>
</tr>
</tbody>
</table>

(Continued on next page)
CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Kenji Inaba (kinaba@tagen.tohoku.ac.jp).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

HEK293T cells were used for overexpression of recombinant human SERCA2b and SERCA2a.

METHOD DETAILS

Construction of plasmids and cell lines
In the present crystallographic studies, we engineered PA-tagged SERCA2a (PA-SERCA2a) using plasmid pcDNA3.1/PA-SERCA2b constructed in our previous study (Ushioda et al., 2016) as a template. The open reading frame (ORF) of SERCA2a was amplified by PCR using primers 5'-taatacgactcactataggg-3' and 5'-tgcggccgcttactccagtattgcaggttccaggtagttgcggcc-3' and subcloned into pcDNA3.1. The ORF of PA-SERCA2b or PA-SERCA2a was isolated from pcDNA3.1 by digestion with NheI and NotI, and inserted into the NheI and NotI sites of the PiggyBac Cumate Switch Inducible Vector (System Biosciences, LLC, CA, USA) to establish a cell line that inducibly expresses PA-SERCA2b or PA-SERCA2a, respectively. For functional assays, we also engineered the F1018G, V1029G and F1018G/V1029G mutants of PA-SERCA2b using the plasmid pcDNA3.1/PA-SERCA2b as a template. The SERCA2b mutants were prepared by site-directed mutagenesis with appropriate primers as follows: 5'-taccctaaaggaccggcccacacgacgagtattac-3' and 5'-cattatgagcagcacccggccaggaaatcccat-3' for F1018G, 5'-cggggaccactagaccccaatatcgtgtctgtgat-3' and 5'-tagtgtctgtctatatcccccagatcaccaggggc-3' for V1029G and the all four primers for F1018G/V1029G.

Crystallization of SERCA2b and SERCA2a
Expression and purification of PA-SERCA2b and PA-SERCA2a were performed as described previously (Ushioda et al., 2016), except that 1 mM sodium butyrate was not included in induction reagents. Briefly, HEK293T cells were co-transfected with the PA-SERCA2b- or PA-SERCA2a-inserted PiggyBac Cumate Switch Inducible vector and Super PiggyBac Transposase Expression Vector (System Biosciences, LLC, CA, USA) using polyethylenimine (Sigma) to establish a cell line stably expressing each of the proteins. High expressions of PA-SERCA2b and HA-SERCA2a were induced with cumate and 50 ng/ml phorbol 12-myristate 13-acetate (PMA). The cells were cultured in DMEM supplemented with 4% inactivated fetal calf serum at 37°C for 48 hr after induction. Harvested cells were solubilized with 1% (w/v) DDM, and PA-SERCA2b and PA-SERCA2a were purified by anti-PA Sepharose beads. During the final step of purification, PA-SERCA2b and PA-SERCA2a were passed through a Superose 6 column (GE Healthcare UK Ltd., Buckinghamshire, UK) equilibrated with buffer containing 100 mM MOPS (pH 6.8), 80 mM KCl, 20% glycerol, 1 mM CaCl2, 1 mM MgCl2, 1 mM DTT and 0.1% n-dodecyl-b-D-maltoside (DDM). PA-SERCA2b and PA-SERCA2a thus purified were concentrated to 10–18 mg ml⁻¹, mixed with 1 mM AMPPCP and incubated overnight at 4°C. After centrifugation at 22,300 g for 30 min, proteins were reconstituted into monoolein at a protein-to-lipid ratio of 2:3 (v/v) (Caffrey and Cherezov, 2009). Crystals of PA-SERCA2b were grown at 20°C in reservoir solution (28–34% polyethylene glycol 250 dimethanol, 100 mM Tris-HCl (pH 7.1–7.3), 100 mM KSCN) for 2–3 days. Similarly, crystals of PA-SERCA2a were grown at 16°C in 28.5–29.5% polyethylene glycol 250 dimethanol, 100 mM Tris-HCl (pH 7.7) and 50 mM NH4NO3 for 2–3 days.

Data collection and structure determination
X-ray diffraction data were collected at SPring-8 beamline BL32XU. Small wedges of data were collected from a number of microcrystals and scaled together. For reduced SERCA2a, a complete dataset was collected from a single crystal. Diffraction data were integrated with XDS (Kabsch, 2010) using the KAMO system (Yamashita et al., 2018) or DIALS (Waterman et al., 2016). Multiple datasets were analyzed with BLEND, followed by scaling and merging with AIMLESS (Evans and Murshudov, 2013) based on CC1/2 values. Initial phases were calculated by molecular replacement with MOLREP using the rabbit SERCA1a E1-AMPPCP structure.
(PDB ID: 1T5S). Model building and refinement were carried out with COOT (Emsley et al., 2010) and PHENIX (Adams et al., 2010), respectively. Final models were refined to reasonable $R_{free}$ values with good geometry, compared with all published crystal structures of comparable resolution.

**Preparation and analysis of SeMet-labeled SERCA2b**

Cells inducibly expressing PA-SERCA2b were cultured in 4% FCS and Dulbecco’s modified Eagles’ medium (DMEM) without methionine. Expression of SeMet-labeled PA-SERCA2b was induced with 30 μg/ml Seleno-L-methionine, 50 nM phorbol 12-myristate 13-acetate and 150 μg/ml cumate. Cells were harvested after 2 days of incubation at 37°C. Purification, crystallization and X-ray diffraction data collection for SeMet-labeled SERCA2b were performed following the same procedures as described above, except that radiation with a wavelength of 0.978 Å was employed for data collection and calculation of an anomalous difference Fourier map to identify SeMet residues in SERCA2b.

**Preparation of microsomal SERCA2b and SERCA2a**

HEK293T cells transfected with WT, F1018G, V1029G or F1018G/V1029G mutants of PA-SERCA2b or WT PA-SERCA2a were incubated in DMEM at 37°C for 2 days. Harvested cells were repeatedly homogenized in 250 mM sucrose, 150 mM KCl, 10 mM Tris-HCl (pH 7.5), 100 mM CaCl$_2$ and 0.2% NaN$_3$ with a Dounce Tissue Grinder (DWK Life Sciences GmbH, Wertheim/Main, Germany), and subsequently centrifuged at 10,000 g for 20 min at 4°C. Homogenates were ultracentrifuged at 100,000 g for 1 hour at 4°C, and pellets were resuspended in 50 mM HEPES (pH 7.0), 100 mM NaCl and 20% glycerol, and homogenized by repeatedly passing the suspension through a 1 mL syringe with a 25 G needle. The concentrations of SERCA2b and SERCA2a in microsomes were estimated by western blotting with anti-SERCA antibody, based on a calibration curve calculated from the band intensity of purified SERCA2b of known concentrations. Band intensities were quantified and analyzed by Image Lab (Bio-Rad Laboratories, Inc., CA, USA).

**ATPase activity assay**

The ATPase activities of SERCA2b and SERCA2a in microsomes were measured as described previously (Ushioda et al., 2016). Briefly, the microsomal SERCA2b or SERCA2a was incubated in buffer containing 50 mM HEPES (pH 7.0), 100 mM NaCl, 20% glycerol, 50 mM NaN$_3$, 5 mM MgCl$_2$, 1 mM EGTA and various concentrations of CaCl$_2$. 1 mM ATP was added to initiate the SERCA ATPase cycle. Each calcium concentration in the reaction buffer was determined using the chelator program (Schoenmakers et al., 1992). The reaction was stopped by 5 mM EGTA, and the resultant solution was mixed with EnzCheck phosphate assay kit (Thermo Fisher Scientific). The mixture was incubated at 22°C for 30 min, and the absorbance at 360 nm was measured by U-3900 Spectrophotometer (Hitachi). Curve fitting of the SERCA2b and SERCA2a activities at different calcium concentrations was performed using Prism7 (Graphpad software) to determine $K_d$ for Ca$^{2+}$, $V_{max}$ and Hill slope values (Table S1).

**QUANTIFICATION AND STATISTICAL ANALYSIS**

Biochemical assays shown in Figure 4 were performed in three independent replicates. Statistical analysis was performed in GraphPad Prism7 using one-way ANOVA analysis followed by Tukey’s multiple comparison test. Values are expressed as means ± SD. Differences with a $p$-value of < 0.05 are considered to be significant.

**DATA AND SOFTWARE AVAILABILITY**

Atomic coordinates and structure factors of human SERCA2b and SERCA2a have been deposited in the Protein Data Bank under accession codes 5ZTF and 6JJU, respectively.